Omzo vs Wellmedr: Compounded GLP-1 Plans Compared
Quick verdict: For clinician-guided compounded semaglutide with a clear starting fee and explicit clinician review language choose Omzo; for lower month-to-month plan pricing, lifetime locked pricing and same-day review choose WellMedr.
Omzo vs Wellmedr compares two services that connect patients with licensed clinicians for GLP-1 treatment options. Omzo emphasizes personalized, clinician-guided compounded semaglutide and tirzepatide with a starting price of $179 and notes that its compounded medications are not FDA-approved. WellMedr promotes GLP-1 plans starting at $89 per month, lifetime locked-in pricing, and same-day review with free overnight shipping. Both note that clinicians determine eligibility and that compounded medications are not evaluated by the FDA.
See Omzo clinician-guided plans
How Omzo and WellMedr differ on pricing and plans
Pricing is a primary difference. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 with clinician-guided, personalized compounded options. WellMedr presents month-to-month plans from $89, with semaglutide plans shown as low as $49 a month in some messaging and tirzepatide plans starting at $89 a month. WellMedr also highlights promotional pricing and lifetime locked-in offers and specific sale messaging on its landing materials. Both providers caution that eligibility, pricing, and terms may change and that patients should confirm details before enrollment.
Clinician oversight, prescriptions, and compounded medication status
Both platforms connect patients with licensed U.S. clinicians who determine medical eligibility and make final prescribing decisions. Omzo explicitly describes a Compounded Medication Program produced by a state licensed sterile compounding pharmacy and states that these compounded drugs are not FDA-approved. WellMedr likewise offers compounded GLP-1 medications from licensed U.S. pharmacies and includes the required notice that compounded medications are not evaluated by the FDA for safety or efficacy.
Delivery, fulfillment, and guarantees
WellMedr emphasizes operational guarantees such as same-day review, free overnight shipping, on-time refills guaranteed, and marketing claims of a money back guarantee if weight is not lost in 90 days as presented on its landing materials. Omzo highlights fast, discreet delivery and FSA and HSA eligibility in its promotional copy but does not present the same-day/refill guarantees shown by WellMedr in the supplied material. Both caution that results vary and that provider assessment and individual factors influence outcomes.
Safety notices and regulatory language
Both providers include regulatory notes that compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. WellMedr includes explicit safety language about potential GLP-1 risks such as thyroid C-cell tumors and medullary thyroid carcinoma and advised seeking immediate care for specific symptoms. Omzo repeats that compounding means the FDA has not reviewed those drugs for safety effectiveness or quality and states clinical services are provided by third party networks of U.S licensed clinicians who determine eligibility.
Comparison table: key criteria
| Criterion | Omzo | WellMedr |
|---|---|---|
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Plans from $89/mo; semaglutide quoted as low as $49/mo in materials |
| Medication type offered | Compounded semaglutide and tirzepatide; may result in prescriptions for branded meds | Compounded GLP-1 medications and branded options referenced |
| Clinician oversight | Licensed U.S. providers review plans; providers decide eligibility | All treatment plans require medical evaluation and clinician approval |
| Regulatory note | Compounded meds not FDA-approved; not reviewed by FDA | Compounded meds not evaluated by FDA; state Boards of Pharmacy regulate compounding |
| Operational promises | Fast, discreet delivery; FSA and HSA eligible | Same-day review; free overnight shipping; on-time refills guaranteed |
Patient experience and marketing claims
Omzo includes patient example language about three months of personalized GLP-1 care and notes that individual results may vary and are not guaranteed. WellMedr’s landing messaging includes promotional sale language and claims such as a money back guarantee in 90 days as presented on the page, which the provider ties to its own materials. Both sources state that the information is not a substitute for medical advice and that clinicians make final treatment decisions.
Compare Omzo medication options
Bottom line and how to choose between Omzo vs Wellmedr
Omzo vs Wellmedr differ most on pricing structure, fulfillment guarantees, regulatory wording, clinician framing, and promotional claims. Choose Omzo if you want clinician-guided, personalized compounded semaglutide or tirzepatide with clear starting fees and an emphasis on clinician review and compounding program details. Choose WellMedr if lower month-to-month pricing, lifetime locked-in pricing and operational guarantees like same-day review and free overnight shipping are the priorities.
Check WellMedr offers and shipping guarantees
Choose Omzo if you prioritize clinician-guided compounded options with stated starting prices and explicit clinician review language. Choose WellMedr if you prioritize lower advertised monthly plan prices, lifetime pricing promises, and logistics guarantees as presented in the supplied materials. Confirm eligibility, medication details, total cost, renewal terms and state availability with each provider before enrolling.